University of Amsterdam-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2020

  1. Beta-blocker effect on ST-segment: A prespecified analysis of the EARLY-BAMI randomised trial

    Open Heart, Vol. 7, Núm. 2

2018

  1. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

    European Heart Journal, Vol. 39, Núm. 14, pp. 1131-1143

  2. New prospects for PCSK9 inhibition?

    European heart journal

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

  2. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: Practical guidance for use in patients at very high cardiovascular risk

    European Heart Journal, Vol. 38, Núm. 29, pp. 2245-2255

2012

  1. Ultrasound and radiology surrogate endpoints in pharmacological studies

    Atherosclerosis, Vol. 224, Núm. 1, pp. 12-24